CTRI/2024/04/065001
Recruiting
Phase 2
Clinical study to Evaluate Efficacy and Safety of EL/DM/01 in participants with Type 2 Diabetes mellitus. - NI
Emil Pharmaceutical Industries Private Limited,0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Sponsor
- Emil Pharmaceutical Industries Private Limited,
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients diagnosed with type 2 diabetes mellitus and are taking oral hypoglycemic agents on regular basis
- •1\. Patients newly diagnosed with type II diabetes mellitus (newly diagnosed cases will be considered as those who have been diagnosed for diabetes mellitus for not more than one year) and those who are not on any oral hypoglycemic agent/insulin
- •For Both the Cohorts:
- •2\.Patients having HbA1C value between 6\.5 to 9\.5 percent (both inclusive) at screening.
- •3\.Patients having Fasting Plasma Glucose between 126 to 250 mg per dl (both inclusive) at screening.
- •4\.Patients having postprandial glucose not more than 350 mg per dl at screening
- •5\.Patient’s ECG does not demonstrate any signs of uncontrolled arrhythmia, acute ischemia.
- •6\.A negative urine pregnancy test for all female patients unless patient has had a hysterectomy, tubal ligation, or is greater 2 years post menopause.
- •7\. Patients willing to follow the procedures as per the study protocol and voluntarily signing informed consent form.
Exclusion Criteria
- •For Both Cohorts:
- •1\. Patients suffering from type\-1 DM or types of Diabetes mellitus other than Type\-2
- •2\. Patients taking Insulin for the management of Diabetes
- •3\. Patients with known history of chronic hepatic or renal disease.
- •4\. Patients with known history of malignancy.
- •5\. Patients with known history of significant cardiovascular event 12 weeks prior to randomization.
- •6\. Patients with known history of major complications of Diabetes like Ketoacidosis, Nephropathy, Neuropathy, Retinopathy, and Diabetic wounds.
- •7\. Patients with known history of chronic, contagious infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV.
- •8\. Patients with known history of active metabolic or gastrointestinal diseases that may interfere with nutrient absorption, metabolism, or excretion, excluding diabetes.
- •9\. History of Use of any other investigational product within 1 month prior to randomization
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Effect of Boozidaan(Pyrethrum Indicum)on Niqris Muzmin(chronic gout)Health Condition 1: M1A9- Chronic gout, unspecifiedCTRI/2021/03/032150Central council for Research in Unani Medicine New Delhi
Unknown
Phase 3
A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood PressureHypertensionJPRN-jRCT2080220304ovartis Pharma K.K.356
Completed
Not Applicable
Clinical safety and efficacy Study â??ROMANTAQUE LOTIONâ??.CTRI/2015/02/005534Mrs Mrinmayee Bhushan Kondhalkar30
Completed
Phase 3
Clinical Study to evaluate efficacy and safety of Eslicarbazepine acetate as an adjunctive therapy in partial-onset seizuresCTRI/2010/091/001194Emcure Pharmaceuticals Ltd., Pune200
Completed
Phase 3
Clinical Trial of S-Amlodipine , Olmesartan and Hydrochlorothiazide combination tablet in the treatment of HypertensioCTRI/2011/06/001820Emcure Pharmaceuticals Ltd Pune200